<p>Immunic, Inc.（納斯達克代碼：IMUX - 獲取免費報告）在目前覆蓋該股票的九家券商中被賦予了 “買入” 的共識推薦，Marketbeat Ratings 報告稱。七位研究分析師對該股票給予了買入推薦，另外兩位則給予了強烈買入推薦。在過去一年中，發佈報告的分析師對該股票的平均一年目標價格為 12.67 美元。</p>
<p>IMUX 已成為幾份研究報告的主題。HC Wainwright 在 2 月 21 日的研究報告中重申了 “買入” 評級，並對 Immunic 的股票設定了 10.00 美元的目標價格。William Blair 在週二對 Immunic 的股票進行了覆蓋，並對該股票設定了 “跑贏大盤” 的評級。D. Boral Capital 在 2 月 26 日的研究報告中重新發布了 “買入” 評級，並對 Immunic 的股票設定了 17.00 美元的目標價格。最後，StockNews.com 在 3 月 20 日的研究報告中將 Immunic 的股票評級從 “持有” 下調至 “賣出”。</p>
<p><strong>查看我們對 Immunic 的最新分析</strong></p>
<h2>Immunic 股票上漲 3.3%</h2>
<p>Immunic 股票在週五開盤價為 1.24 美元。該公司的市值為 1.117 億美金，市盈率為-1.01，貝塔值為 1.89。Immunic 的 12 個月最低價為 0.92 美元，最高價為 2.11 美元。該公司的 50 日移動平均價格為 1.08 美元，200 日移動平均價格為 1.21 美元。</p>
<h2>對 Immunic 的對沖基金看法</h2>
<p>一些對沖基金最近調整了對 IMUX 的持股。Jane Street Group LLC 在第三季度將其在 Immunic 的股份增加了 121.4%。Jane Street Group LLC 現在擁有 70,299 股該公司的股票，價值 116,000 美元，此前在上個季度購買了 38,553 股。HB Wealth Management LLC 在第四季度購買了 Immunic 的新股份，價值約 81,000 美元。State Street Corp 在第三季度將其在 Immunic 的持股增加了 7.5%。State Street Corp 現在擁有 167,145 股該公司的股票，價值 276,000 美元，此前在上個季度購買了 11,642 股。Connor Clark &amp; Lunn Investment Management Ltd. 在第三季度將其在 Immunic 的持股增加了 70.8%。Connor Clark &amp; Lunn Investment Management Ltd. 現在擁有 102,257 股該公司的股票，價值 169,000 美元，此前在上個季度購買了 42,383 股。最後，Virtu Financial LLC 在第三季度購買了 Immunic 的新股份，價值約 50,000 美元。對沖基金和其他機構投資者持有該公司 51.82% 的股票。</p>
<h2>Immunic 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Immunic, Inc. 是一家生物技術公司，開發一系列選擇性口服免疫療法，用於治療美國和德國的慢性炎症和自身免疫性疾病。其主要開發項目是 IMU-838，目前正在進行第三階段臨牀試驗，旨在治療多發性硬化症，包括複發性和進展性多發性硬化症；以及中度至重度潰瘍性結腸炎。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Immunic</li>
<li>市盈率計算：如何評估股票</li>
<li>便士股票 SurgePays 上漲 70%：買入的一個理由，賣出的五個理由</li>
<li>股息捕捉策略：您需要知道的事項</li>
<li>三大飲料股票帶來豐厚利潤</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>CarMax 和 Carvana：引領二手車市場</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於 Immunic 嗎？</h2>
<p>在您考慮 Immunic 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Immunic 並不在名單上。</p>
<p>雖然 Immunic 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IMUX

<p>Immunic, Inc.（納斯達克代碼：IMUX）獲得了九家券商的共識推薦評級為 “買入”，其中七位分析師給予 “買入” 評級，兩位分析師給予 “強力買入” 評級。平均一年期目標價為 12.67 美元。最近的報告包括 HC Wainwright 的 10.00 美元目標價和 D. Boral Capital 的 17.00 美元目標價。Immunic 的股票開盤價為 1.24 美元，市值為 1.117 億美金。對沖基金持有該公司 51.82% 的股份，該公司專注於開發慢性炎症和自身免疫疾病的治療方案</p>

<p>Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned a consensus recommendation of &#34;Buy&#34; from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $12.67.</p>
<div class="lb-trans"><p>Immunic, Inc.（納斯達克代碼：IMUX - 獲取免費報告）在目前覆蓋該股票的九家券商中被賦予了 “買入” 的共識推薦，Marketbeat Ratings 報告稱。七位研究分析師對該股票給予了買入推薦，另外兩位則給予了強烈買入推薦。在過去一年中，發佈報告的分析師對該股票的平均一年目標價格為 12.67 美元。</p>
</div><p>IMUX has been the subject of several research reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. William Blair initiated coverage on shares of Immunic in a report on Tuesday. They set an &#34;outperform&#34; rating on the stock. D. Boral Capital reissued a &#34;buy&#34; rating and issued a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. Finally, StockNews.com lowered shares of Immunic from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Thursday, March 20th.</p>
<div class="lb-trans"><p>IMUX 已成為幾份研究報告的主題。HC Wainwright 在 2 月 21 日的研究報告中重申了 “買入” 評級，並對 Immunic 的股票設定了 10.00 美元的目標價格。William Blair 在週二對 Immunic 的股票進行了覆蓋，並對該股票設定了 “跑贏大盤” 的評級。D. Boral Capital 在 2 月 26 日的研究報告中重新發布了 “買入” 評級，並對 Immunic 的股票設定了 17.00 美元的目標價格。最後，StockNews.com 在 3 月 20 日的研究報告中將 Immunic 的股票評級從 “持有” 下調至 “賣出”。</p>
</div><p><strong>View Our Latest Analysis on Immunic</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Immunic 的最新分析</strong></p>
</div><h2>Immunic Trading Up 3.3 %</h2>
<div class="lb-trans"><h2>Immunic 股票上漲 3.3%</h2>
</div><p>Shares of Immunic stock opened at $1.24 on Friday. The firm has a market capitalization of $111.70 million, a PE ratio of -1.01 and a beta of 1.89. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The business's 50-day moving average price is $1.08 and its 200-day moving average price is $1.21.</p>
<div class="lb-trans"><p>Immunic 股票在週五開盤價為 1.24 美元。該公司的市值為 1.117 億美金，市盈率為-1.01，貝塔值為 1.89。Immunic 的 12 個月最低價為 0.92 美元，最高價為 2.11 美元。該公司的 50 日移動平均價格為 1.08 美元，200 日移動平均價格為 1.21 美元。</p>
</div><h2>Hedge Funds Weigh In On Immunic</h2>
<div class="lb-trans"><h2>對 Immunic 的對沖基金看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of IMUX. Jane Street Group LLC grew its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. HB Wealth Management LLC purchased a new stake in Immunic in the 4th quarter worth approximately $81,000. State Street Corp grew its position in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark &amp; Lunn Investment Management Ltd. grew its position in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter valued at approximately $50,000. Hedge funds and other institutional investors own 51.82% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近調整了對 IMUX 的持股。Jane Street Group LLC 在第三季度將其在 Immunic 的股份增加了 121.4%。Jane Street Group LLC 現在擁有 70,299 股該公司的股票，價值 116,000 美元，此前在上個季度購買了 38,553 股。HB Wealth Management LLC 在第四季度購買了 Immunic 的新股份，價值約 81,000 美元。State Street Corp 在第三季度將其在 Immunic 的持股增加了 7.5%。State Street Corp 現在擁有 167,145 股該公司的股票，價值 276,000 美元，此前在上個季度購買了 11,642 股。Connor Clark &amp; Lunn Investment Management Ltd. 在第三季度將其在 Immunic 的持股增加了 70.8%。Connor Clark &amp; Lunn Investment Management Ltd. 現在擁有 102,257 股該公司的股票，價值 169,000 美元，此前在上個季度購買了 42,383 股。最後，Virtu Financial LLC 在第三季度購買了 Immunic 的新股份，價值約 50,000 美元。對沖基金和其他機構投資者持有該公司 51.82% 的股票。</p>
</div><h2>Immunic Company Profile</h2>
<div class="lb-trans"><h2>Immunic 公司簡介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.</p>
<div class="lb-trans"><p>Immunic, Inc. 是一家生物技術公司，開發一系列選擇性口服免疫療法，用於治療美國和德國的慢性炎症和自身免疫性疾病。其主要開發項目是 IMU-838，目前正在進行第三階段臨牀試驗，旨在治療多發性硬化症，包括複發性和進展性多發性硬化症；以及中度至重度潰瘍性結腸炎。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Immunic</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Top 3 Beverage Stocks Pouring Out Profits</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>CarMax and Carvana: Steering the Used Car Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Immunic</li>
<li>市盈率計算：如何評估股票</li>
<li>便士股票 SurgePays 上漲 70%：買入的一個理由，賣出的五個理由</li>
<li>股息捕捉策略：您需要知道的事項</li>
<li>三大飲料股票帶來豐厚利潤</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>CarMax 和 Carvana：引領二手車市場</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMUX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunic Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 Immunic 嗎？</h2>
</div><p>Before you consider Immunic, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Immunic 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Immunic 並不在名單上。</p>
</div><p>While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Immunic 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Immunic, Inc. (NASDAQ:IMUX) 獲得券商的平均評級為 “買入”